Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-GC1008 PET-guided GC1008 study in malignant glioma
NL-OMON36507Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of fresolimumab in malignant glioma, glioblastoma (GBM) and anaplastic glioma (2 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Quantification of 89Zr-GC1008 uptake in suspected malignant glioma and Quantification of 89Zr-GC1008 uptake in relapsed malignant glioma. Started Jan 2012; status: active, not recruiting.
02
Drugs
fresolimumab
03
Conditions
malignant gliomaglioblastoma (GBM)anaplastic glioma
Beyond the preview
Go deeper on NL-OMON36507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36507.